Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Section for Breast Oncology

7 publications found

Hugenschmidt H, Labori KJ, Brunborg C, Verbeke CS, Seeberg LT, Schirmer CB, Renolen A, Borgen EF, Naume B, Wiedswang G (2020)
Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma
Ann Surg, 271 (3), 549-558
DOI 10.1097/SLA.0000000000003035, PubMed 30216219

Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163

Kyte JA, Røssevold A, Falk RS, Naume B (2020)
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
J Transl Med, 18 (1), 252
DOI 10.1186/s12967-020-02424-7, PubMed 32576225

Lofterød T, Frydenberg H, Flote V, Eggen AE, McTiernan A, Mortensen ES, Akslen LA, Reitan JB, Wilsgaard T, Thune I (2020)
Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study
Breast Cancer Res Treat, 182 (1), 215-227
DOI 10.1007/s10549-020-05679-2, PubMed 32436147

Nilssen Y, Brustugun OT, Eriksen MT, Haug ES, Naume B, Møller B (2020)
Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016
BMC Cancer, 20 (1), 488
DOI 10.1186/s12885-020-06979-y, PubMed 32473650

Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan Ø, Liestøl K, Vitelli V, Frigessi A, Langerød A, Mathelier A, OSBREAC, Engebråten O, Kristensen V, Wedge DC, Van Loo P, Caldas C, Børresen-Dale AL, Russnes HG, Lingjærde OC (2020)
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091

von der Lippe Gythfeldt H, Lien T, Tekpli X, Silwal-Pandit L, Borgen E, Garred Ø, Skjerven H, Schlichting E, Lundgren S, Wist E, Naume B, Kristensen V, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2020)
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer
DOI 10.1002/ijc.33108, PubMed 32488909

 
Page visits: 410642